HC Wainwright Predicts Stronger Earnings for Co-Diagnostics

Co-Diagnostics, Inc. (NASDAQ:CODX) – HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for Co-Diagnostics in a note issued to investors on Monday, May 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.33). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Co-Diagnostics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Co-Diagnostics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.68) EPS.

CODX has been the subject of several other research reports. D Boral Capital upgraded Co-Diagnostics to a “strong-buy” rating in a research report on Monday, April 28th. D. Boral Capital initiated coverage on Co-Diagnostics in a report on Monday, April 28th. They set a “buy” rating and a $10.00 target price for the company.

Co-Diagnostics Price Performance

Shares of NASDAQ CODX opened at $0.31 on Wednesday. The business’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.67. Co-Diagnostics has a 1-year low of $0.27 and a 1-year high of $2.23. The stock has a market capitalization of $10.25 million, a P/E ratio of -0.22 and a beta of 0.84.

Co-Diagnostics (NASDAQ:CODX) last issued its earnings results on Thursday, May 8th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.09. Co-Diagnostics had a negative return on equity of 54.94% and a negative net margin of 563.93%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.38 million.

Institutional Trading of Co-Diagnostics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of Co-Diagnostics by 7.5% during the 4th quarter. Geode Capital Management LLC now owns 345,511 shares of the company’s stock valued at $259,000 after purchasing an additional 24,236 shares during the last quarter. Thompson Davis & CO. Inc. grew its position in Co-Diagnostics by 37.8% during the 4th quarter. Thompson Davis & CO. Inc. now owns 57,200 shares of the company’s stock worth $43,000 after purchasing an additional 15,700 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Co-Diagnostics during the 3rd quarter worth about $55,000. Hedge funds and other institutional investors own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.